PMID- 25217331
OWN - NLM
STAT- MEDLINE
DCOM- 20150701
LR  - 20211021
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 12
DP  - 2014 Sep 13
TI  - Over-expression of a poor prognostic marker in prostate cancer: AQP5 promotes 
      cells growth and local invasion.
PG  - 284
LID - 10.1186/1477-7819-12-284 [doi]
LID - 284
AB  - BACKGROUND: The aquaporins (AQPs), water channel proteins, are known playing a 
      major role in transcellular and transepithelial water movement; they also exhibit 
      several properties related to tumor development. The aim of the present study is 
      to elucidate whether the expression of AQP5 is a strong prognostic biomarker for 
      prostate cancer, and the potential role in the progression of prostate cancer 
      cells. METHODS: AQP5 expression was measured in 60 prostate cancer tissues and 
      cells (both PC-3 and LNCaP) by immunohistochemistry and immunofluorescence assay. 
      AQP5 gene amplification was detected with FISH (fluorescence in situ 
      hybridization). Proliferation and migration of cells and AQP5 siRNA cells were 
      detected with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
      and Boyden chambers. Circulating tumor cells (CTCs) were detected by imFISH 
      staining (CEP8-CD45-DAPI) assay. RESULTS: The results showed that in 60 tumor 
      specimens, 19 (31.7%) patients showed high level of AQP5 expression, while 30 
      (50.0%) showed a moderate, intermediate level of staining, and 11 (18.3%) showed 
      an absence of AQP5 staining, respectively. High-expression of AQP5 protein 
      frequently accompanied gene amplification detection with FISH. The AQP5 
      over-expression was also associated with TNM stage (P=0.042), and lymph node 
      metastasis (P=0.001). The relationships between age or tumor size with the 
      expression of AQP5 were not significant (P>0.05). A positive correlation between 
      the number of CTCs and AQP5 expression (P<0.05) was demonstrated. In addition, 
      patients who were negative for AQP5 had superior cumulative survival rate than 
      those who were positive for it. Over-expression of AQP5 protein was also found in 
      prostate cancer cells and cell proliferation and migration were significantly 
      attenuated by AQP5-siRNA. CONCLUSIONS: We concluded that AQP5 in prostate cancer 
      was an independent prognostic indicator. AQP5 over-expression was likely to play 
      a role in cell growth and metastasis. These conclusions suggest that AQP5 may be 
      an effective therapeutic target for prostate cancer.
FAU - Li, Jianping
AU  - Li J
FAU - Wang, Ziming
AU  - Wang Z
AD  - Department of Urology, the Second Affiliated Hospital of Medical College, Xi'an 
      Jiaotong University, Xi'an, Shaanxi Province 710004, China. 
      JianpingLi0292@163.com.
FAU - Chong, Tie
AU  - Chong T
FAU - Chen, Haiwen
AU  - Chen H
FAU - Li, Hechen
AU  - Li H
FAU - Li, Gang
AU  - Li G
FAU - Zhai, Xiaoqiang
AU  - Zhai X
FAU - Li, Youfang
AU  - Li Y
LA  - eng
PT  - Journal Article
DEP - 20140913
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (AQP5 protein, human)
RN  - 0 (Aquaporin 5)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aquaporin 5/genetics/*metabolism
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Blotting, Western
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Prostatectomy
MH  - Prostatic Neoplasms/genetics/*metabolism/mortality/surgery
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Analysis
MH  - Up-Regulation
PMC - PMC4247740
EDAT- 2014/09/14 06:00
MHDA- 2015/07/02 06:00
PMCR- 2014/09/13
CRDT- 2014/09/14 06:00
PHST- 2014/07/15 00:00 [received]
PHST- 2014/09/02 00:00 [accepted]
PHST- 2014/09/14 06:00 [entrez]
PHST- 2014/09/14 06:00 [pubmed]
PHST- 2015/07/02 06:00 [medline]
PHST- 2014/09/13 00:00 [pmc-release]
AID - 1477-7819-12-284 [pii]
AID - 1817 [pii]
AID - 10.1186/1477-7819-12-284 [doi]
PST - epublish
SO  - World J Surg Oncol. 2014 Sep 13;12:284. doi: 10.1186/1477-7819-12-284.